Irène Frachon, Dominique Dupagne, et le Manifeste des 30

Mediator: des médecins dénoncent les liens d’intérêt avec Servier

Manifeste-des-30
30 médecins, philosophes et personnalités engagées, rappellent au laboratoire SERVIER et à la profession médicale leurs obligations légales et morales. Comme @DES_Journal (N°113), signez la pétition!

Le contenu de ce post est republié du site manifestedes30.com

Nous, signataires de ce manifeste, exhortons les professionnels de santé à reconsidérer leurs liens avec le groupe pharmaceutique SERVIER, laboratoire mis en examen pour des comportements d’une extrême gravité à l’origine de milliers de maladies cardiaques graves et de décès.

Début 2014, le procureur de Paris annonçait la fin de l’enquête pénale menée par les juges d’instruction du Pôle Santé de Paris depuis le retrait du Mediator fin 2009. L’enquête et notamment le rapport d’expertise pénal confirmaient le dramatique bilan humain ainsi que l’existence d’éléments graves justifiant des mises en examen de l’entreprise SERVIER pour « tromperie aggravée avec mise en danger de l’homme”, “escroquerie”, “homicides et blessures involontaires”, “trafic d’influence et prise illégale d’intérêts”.

Plutôt que de faire amende honorable, le laboratoire SERVIER poursuit depuis plusieurs années une guérilla judiciaire pour retarder à la fois le procès pénal et surtout l’indemnisation des victimes au civil. Trahissant ses engagements publics de réparation, il conteste sans relâche chaque étape du processus d’indemnisation jusqu’à contraindre récemment l’Etat (via l’Oniam*) à se substituer à lui et à indemniser des victimes avec des fonds publics !

Alors que l’état de santé de nombreuses victimes ne cesse de se dégrader, le laboratoire SERVIER pousse nombre d’entre elles au désespoir et à la conviction « qu’en fait, SERVIER attend leur mort ». Cette attitude est contraire à l’éthique scientifique et pharmaceutique.

Dans ces conditions, les signataires de ce manifeste déplorent que le laboratoire SERVIER reste un sponsor favorablement accueilli par une partie de la communauté médicale, certaines sociétés savantes et de nombreux leaders d’opinion médicaux.

Ils appellent solennellement les médecins, soignants et leurs instances représentatives à réévaluer la pertinence des liens les unissant au laboratoire Servier, et à vérifier si ces partenariats sont compatibles avec les principes fondamentaux de la déontologie médicale. ”

Comme @DES_Journal (113), SIGNEZ la pétition à l’initiative d’Irène Frachon et de Dominique Dupagne.

En savoir plus
  • Mediator: des médecins dénoncent les liens d’intérêt avec Servier,
    Le Figaro Santé, 26/08/2015.
  • Communique_de_presse_Indemnisations_Mediator,
    Le Groupe Servier, 27 août 2015.

Women’s Sexual Desire

When pharma turns lack of desire into a disease…

woman-sexual-desire image
When pharma turns lack of desire into a disease…
Sources and more information

FDA drug approval rate reaches new high

The FDA Is Basically Approving Everything. Here’s The Data To Prove It

fda-approval-rates
Remember when the FDA rejected drugs? The FDA points out that one reason that drug approval rates are going up is because it is doing its job, as defined by Congress

We just got treated to a whole lot of drama last week as to whether Addyi, a drug to boost women’s libidos, would be approved. But based on data analysis commissioned by Forbes from BioMedTracker, that approval was probably a foregone conclusion.”…

… “But the risks of speeding up approvals should be pretty clear, too. In the late 1990s and early 2000s, there was a boom of new drug approvals. In 1999, the FDA approved two drugs that became synonymous with drug safety scandals: Vioxx, which was withdrawn from the market by Merck, and Avandia, made by GlaxoSmithKline, which later had its use severely restricted. The approval boom is good only so long as it doesn’t trigger another drug safety conference.”

Read The FDA Is Basically Approving Everything. Here’s The Data To Prove It, Forbes, AUG 20, 2015.

Could a simple blood test predict breast cancer relapse?

Mutation-tracking blood test could predict breast cancer relapse months in advance

early-stage-breast-cancer image
Researchers report that circulating tumor DNA in patients’ blood can be used to predict the likelihood of early-stage breast cancer recurring after apparently curative treatment. C. Bickel / Science Translational Medicine.

Scientists have developed a blood test for breast cancer able to identify which patients will suffer a relapse after treatment, months before tumours are visible on hospital scans.

2015 Study Abstract

Predicting whether a cancer patient will relapse remains a formidable challenge in modern medicine. Fortunately, circulating tumor DNA (ctDNA) present in the blood may give clues on residual disease—cancer cells left behind to seed new tumors even after treatment. Garcia-Murillas et al. developed a personalized ctDNA assay based on digital polymerase chain reaction to track mutations over time in patients with early-stage breast cancer who had received apparently curative treatments, surgery, and chemotherapy. Mutation tracking in serial samples accurately predicted metastatic relapse—in several instances, months before clinical relapse (median of ~8 months). Such unprecedented early prediction could allow for intervention before the reappearance of cancer in high-risk patients. In addition, the authors were able to shed light on the genetic events driving such metastases, by massively parallel sequencing of the ctDNA, which could inform new drug-based therapies on the basis of the patients’ individual mutations.

Sources and More Information
  • New ‘mutation-tracking’ blood test could predict breast cancer relapse months in advance, MedicalXpress, August 26, 2015.
  • Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer, Science Translational Medicine: Vol. 7, Issue 302, pp. 302ra133, DOI: 10.1126/scitranslmed.aab0021, 26 Aug 2015.

La fracturation hydraulique, le champ de bataille…

Les dessins d’AGIR pour l’environnement

la-fracturation-hydraulique
Tous, nous pouvons pousser pour que la France s’engage dans une transition énergétique qui tourne le dos aux énergies fossiles et fissiles et consacre son énergie, son effort de recherche, ses investissements, aux énergies renouvelables et à l’efficacité énergétique.

Fin 2013, un rapport sur les alternatives à la fracturation hydraulique était présenté à l’Office Parlementaire d’Évaluation des Choix Scientifiques et Techniques (OPECST) par deux députés ouvertement pro gaz de schiste Christian Bataille et Jean-Claude Lenoir…

Denis Baupin, vice président de l’Assemblée Nationale et membre de l’OPECST est l’un des deux seuls à avoir voté contre ce rapport. Il a répondu aux questions d’Agir pour l’Environnement.

  • Pourquoi avoir voté contre le rapport de Christian Bataille et Jean-Claude Lenoir sur les alternatives à la fracturation hydraulique?
  • Comment expliquez-vous que les parlementaires et l’OPECST – moins les deux voix écologistes – aient voté à l’unanimité pour la promotion de la facturation hydraulique?
  • Le Ministre de l’environnement vient de refuser de signer la cessation de 7 permis pétroliers (qui visaient l’exploitation de pétrole de schiste dans le bassin parisien) à la société Hess Oil. Comment analyser ce refus? Est-ce une victoire pour les anti gaz de schiste?

En savoir plus

  • #gazdeschiste: 3 questions à @Denis_Baupin sur le Rapport Bataille/Lenoir,
    Agir pour l’Environnement, 02/12/2013.
  • Les techniques alternatives à la fracturation hydraulique pour l’exploration et l’exploitation des hydrocarbures non conventionnels (Rapport d’étape),
    senat, 5 juin 2013.
  • Notre album de posters sur Flickr, les posts tagués fracking.

Major crackdown on drug firms corruption in the NHS, transparency is needed

Jeremy Hunt: NHS bosses face jail over links to drug firms

jeremy-hunt
Last month, an undercover investigation by The Telegraph disclosed that senior health staff who help choose drugs for the NHS were paid to work as consultants to pharmaceutical firms keen for the health service to opt for their products. Jeremy Hunt, the Health Secretary, said that hospitals and GP groups will be required to keep a register of hospitality and gifts from pharmaceutical firms to health service staff.

Senior medical staff will be forced to declare all gifts and hospitality they receive from drug companies or face the sack and the threat of jail.
In a major crackdown on corruption in the NHS, all hospitals and GP groups will be required to keep a register of hospitality and gifts from pharmaceutical firms to health service staff.

Jeremy Hunt, the Health Secretary, says he was forced to act after the Telegraph uncovered “disturbing” evidence of senior NHS managers being paid thousands of pounds and taken on expensive trips by firms lobbying to get their drugs used.

The transparency, or “Sunshine rule”, will be mandatory from next year and any member of staff who fails to declare full details of perks they receive will face disciplinary action.”

Read Jeremy Hunt: NHS bosses face jail over links to drug firms and Lavish trips laid on by drugs firms to ‘sway’ NHS staff, via an undercover investigation by The Telegraph,
22 Aug and 22 Jul 2015.

Ductal carcinoma in situ recurrence prevention by radiotherapy not improving mortality rates

Breast Cancer Mortality After a Diagnosis of Ductal Carcinoma In Situ

breast-cast
The risk of death increases after a diagnosis of an ipsilateral second primary invasive breast cancer, but prevention of these recurrences by radiotherapy does not diminish breast cancer mortality at 10 years.
Breast cast image by Renee Prisble.

2015 Study Abstract

Importance
Women with ductal carcinoma in situ (DCIS), or stage 0 breast cancer, often experience a second primary breast cancer (DCIS or invasive), and some ultimately die of breast cancer.

Objective
To estimate the 10- and 20-year mortality from breast cancer following a diagnosis of DCIS and to establish whether the mortality rate is influenced by age at diagnosis, ethnicity, and initial treatment received.

Design, Setting, and Participants
Observational study of women who received a diagnosis of DCIS from 1988 to 2011 in the Surveillance, Epidemiology, and End Results (SEER) 18 registries database. Age at diagnosis, race/ethnicity, pathologic features, date of second primary breast cancer, cause of death, and survival were abstracted for 108 196 women. Their risk of dying of breast cancer was compared with that of women in the general population. Cox proportional hazards analysis was performed to estimate the hazard ratio (HR) for death from DCIS by age at diagnosis, clinical features, ethnicity, and treatment.

Main Outcomes and Measures
Ten- and 20-year breast cancer–specific mortality.

Results
Among the 108 196 women with DCIS, the mean (range) age at diagnosis of DCIS was 53.8 (15-69) years and the mean (range) duration of follow-up was 7.5 (0-23.9) years. At 20 years, the breast cancer–specific mortality was 3.3% (95% CI, 3.0%-3.6%) overall and was higher for women who received a diagnosis before age 35 years compared with older women (7.8% vs 3.2%; HR, 2.58 [95% CI, 1.85-3.60]; P < .001) and for blacks compared with non-Hispanic whites (7.0% vs 3.0%; HR, 2.55 [95% CI, 2.17-3.01]; P < .001). The risk of dying of breast cancer increased after experience of an ipsilateral invasive breast cancer (HR, 18.1 [95% CI, 14.0-23.6]; P < .001). A total of 517 patients died of breast cancer following a DCIS diagnosis (mean follow-up, 7.5 [range, 0-23.9] years) without experiencing an in-breast invasive cancer prior to death. Among patients who received lumpectomy, radiotherapy was associated with a reduction in the risk of ipsilateral invasive recurrence at 10 years (2.5% vs 4.9%; adjusted HR, 0.47 [95% CI, 0.42-0.53]; P < .001) but not of breast cancer–specific mortality at 10 years (0.8% vs 0.9%; HR, 0.86 [95% CI, 0.67-1.10]; P = .22).

Conclusions and Relevance
Important risk factors for death from breast cancer following a DCIS diagnosis include age at diagnosis and black ethnicity. The risk of death increases after a diagnosis of an ipsilateral second primary invasive breast cancer, but prevention of these recurrences by radiotherapy does not diminish breast cancer mortality at 10 years.

Sources and More Information

No Family History, the Environmental Links to Breast Cancer

Are Everyday Products From Cosmetics To Household Cleaners Causing The High Rates Of Breast Cancer?

no-family-history book cover
Are Everyday Products From Cosmetics To Household Cleaners Causing The High Rates Of Breast Cancer?

No Family History presents compelling evidence of environmental links to breast cancer, ranging from everyday cosmetics to industrial waste. Sabrina McCormick weaves the story of one survivor with no family history into a powerful exploration of the big business of breast cancer. As drugs, pink products, and corporate sponsorships generate enormous revenue to find a cure, a growing number of experts argue that we should instead increase focus on prevention reducing environmental exposures that have contributed to the sharp increase of breast cancer rates. But the dollars continue to pour into the search for a cure, and the companies that profit, including some pharmaceutical and cosmetics companies, may in fact contribute to the environmental causes of breast cancer. No Family History shows how profits drive our public focus on the cure rather than prevention, and suggests new ways to reduce breast cancer rates in the future.

Sources and more information

Structural anomalies of the cervix and vagina in women enrolled in the Diethylstilbestrol Adenosis Project

Prevalence rate of the anomalies lower among subjects who had been pregnant, and higher among those with later age at menarche

woman-thinking
DiEthylStilbestrol usage review buttress the need for adequate and rigorous research into the use of drugs in pregnancy and ensure that they do more good than harm before being introduced for consumption. Contemplation by Rennett Stowe.

1984 Study Abstract

Among women exposed in utero to diethylstilbestrol (DES) and enrolled in the Diethylstilbestrol Adenosis (DESAD) Project, structural anomalies of the cervix or vagina were found in 25% of the 1,655 subjects identified by review of prenatal records, 43% of the 800 who themselves requested entry into the project, and 49% of the 1,089 referred by physicians but in only 2% of the 963 control subjects. Among the 367 cases found by record review to have complete information on the DES exposure, multivariate analysis indicated close association of the anomalies with the gestational week of first exposure and the total dose. Also, the prevalence rate of the anomalies was lower among subjects who had been pregnant and higher among those with later age at menarche.

Sources and more information
  • Structural anomalies of the cervix and vagina in women enrolled in the Diethylstilbestrol Adenosis (DESAD) Project, Am J Obstet Gynecol, NCBI PMID: 6691382, 1984 Jan 1;148(1):59-66.
More DES DiEthylStilbestrol Resources

Les vendeurs de maladies

Cash investigation, Saison 1 Episode 7, 2015

Cash investigation, Saison 1 Episode 7 (partie 1),
Elise Lucet, France 2, vidéo publiée le 21 juillet 2015

Plus d’information
  • Pour ce premier numéro, Elise Lucet s’intéresse aux “vendeurs de maladies“, ces laboratoires qui inventent de toutes pièces une pathologie pouvant correspondre à la nouvelle molécule qu’ils viennent de mettre au point, parfois malgré des effets secondaires avérés, pour lesquels ils ont déjà prévu de nouveaux médicaments.
  • Regardez cette liste de vidéos sur l’industrie pharmaceutique sur notre chaîneYouTube.